The Drug Safety Update also provides advice on management strategies stating all patients should receive prophylaxis for P jirovecii pneumonia during treatment with idelalisib and for up to 2–6 months after stopping. The duration of post-treatment prophylaxis should be based on clinical judgment, taking into account the patient’s risk factors such as concomitant corticosteroid treatment and prolonged neutropenia.
The manufacturer had also issued an advisory letter to healthcare professionals.